Read by QxMD icon Read

Acta Oncologica

Eero Pukkala, Gerda Engholm, Lise Kristine Højsgaard Schmidt, Hans Storm, Staffan Khan, Mats Lambe, David Pettersson, Elínborg Ólafsdóttir, Laufey Tryggvadóttir, Tiina Hakanen, Nea Malila, Anni Virtanen, Tom Børge Johannesen, Siri Larønningen, Giske Ursin
BACKGROUND: The Nordic Cancer Registries are among the oldest population-based registries in the world, with more than 60 years of complete coverage of what is now a combined population of 26 million. However, despite being the source of a substantial number of studies, there is no published paper comparing the different registries. Therefore, we did a systematic review to identify similarities and dissimilarities of the Nordic Cancer Registries, which could possibly explain some of the differences in cancer incidence rates across these countries...
December 11, 2017: Acta Oncologica
Waqar Haque, Gary D Lewis, Vivek Verma, Jorge G Darcourt, E Brian Butler, Bin S Teh
PURPOSE: The standard of care for locally advanced bladder cancer (LABC) is neoadjuvant chemotherapy followed by cystectomy. However, the role of adjuvant therapy is unclear. The purpose of this study was to evaluate the outcomes of adjuvant chemotherapy for patients with LABC following neoadjuvant chemotherapy and cystectomy, and to determine whether select patients may benefit from adjuvant chemotherapy. METHODS: The National Cancer Data Base (NCDB) was queried (2004-2013) for patients with newly diagnosed pT3-4N0-3M0 bladder cancer that received neoadjuvant chemotherapy and cystectomy...
December 11, 2017: Acta Oncologica
Naohito Beppu, Fumihiko Kimura, Ryo Okamoto, Yoshihiko Nakamoto, Naohiro Tomita, Hidenori Yanagi, Naoki Yamanaka
No abstract text is available yet for this article.
December 11, 2017: Acta Oncologica
Laura S Porter, Francis J Keefe
No abstract text is available yet for this article.
December 8, 2017: Acta Oncologica
M Kandi, L Hoffmann, D Sloth Moeller, H H Schmidt, M M Knap, A A Khalil
OBJECTIVES: Local recurrence (rec) in lung cancer is associated with poor survival. This study examined whether the pattern of failure is associated with the most PET avid volume in the planning-FDG-PET/CT scan (p-PET/CT). METHODS: 162 consecutive inoperable NSCLC patients (pts) receiving radiotherapy between January 2012 and April 2014 were reviewed. Radiotherapy was delivered in 2 Gy/fraction (5f/week) to a total dose of 60-66 Gy. Pts were followed with CT scans every third month...
December 5, 2017: Acta Oncologica
Martin Berg, Ebbe L Lorenzen, Ingelise Jensen, Mette S Thomsen, Christina Maria Lutz, Lasse Refsgaard, Henrik D Nissen, Birgitte V Offersen
PURPOSE: The potential benefits from respiratory gating (RG) compared to free-breathing (FB) regarding target coverage and dose to organs at risk for breast cancer patients receiving post-operative radiotherapy (RT) in the DBCG HYPO multicentre trial are reported. MATERIAL AND METHODS: Patients included in the DBCG HYPO trial were randomized between 50 Gy in 25 fractions (normofractionated) versus 40 Gy in 15 fractions (hypofractionated). A tangential forward field-in-field dose planning technique was used to cover the clinical target volume (CTV) with the intent to limit dose to the left anterior descending coronary artery (LADCA) to 20 Gy and 17 Gy in the normo- and hypofractionated arms, respectively...
December 5, 2017: Acta Oncologica
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
Gitte Lee Mortensen, Ivan Bredbjerg Madsen, Randi Krogsgaard, Bent Ejlertsen
BACKGROUND: In recent years, the prognosis of metastatic breast cancer (MBC) has improved with more effective therapies applicable to a wider range of patients. To many patients, a MBC diagnosis thus initiates a prolonged course of illness and treatment. This qualitative study aimed to explore the long-term health-related quality of life (HRQoL) and support needs in MBC patients of all ages in the Danish context. MATERIAL AND METHODS: Eighteen MBC patients participated in five qualitative focus group interviews that were analyzed using content analysis and a constructivist approach...
December 5, 2017: Acta Oncologica
Carsten Brink, Ebbe L Lorenzen, Simon Long Krogh, Jonas Westberg, Martin Berg, Ingelise Jensen, Mette Skovhus Thomsen, Esben Svitzer Yates, Birgitte Vrou Offersen
INTRODUCTION: The current study evaluates the data quality achievable using a national data bank for reporting radiotherapy parameters relative to the classical manual reporting method of selected parameters. METHODS: The data comparison is based on 1522 Danish patients of the DBCG hypo trial with data stored in the Danish national radiotherapy data bank. In line with standard DBCG trial practice selected parameters were also reported manually to the DBCG database...
December 5, 2017: Acta Oncologica
Marianne Ewertz, Lotte Holm Land, Susanne Oksbjerg Dalton, Deirdre Cronin-Fenton, Maj-Britt Jensen
BACKGROUND: While comorbidity indices are useful for describing trends in survival, information on specific comorbidities is needed for the clinician advising the individual breast cancer patient on her treatment. Here we present an analysis of overall survival, breast cancer-specific mortality, and effect of medical adjuvant treatment among breast cancer patients suffering from 12 major comorbidities compared with breast cancer patients without comorbidities. MATERIAL AND METHODS: The study population was identified from the Danish Breast Cancer Cooperative Group and included 59,673 women without prior cancer diagnosed with early-stage breast cancer in Denmark from 1990 to 2008 with an estimated median potential follow-up of 14 years and 10 months...
December 5, 2017: Acta Oncologica
A Mäkitie, M Ruuskanen, J Bentzen, E Brun, M Gebre-Medhin, S Friesland, E Marsk, L Hammarstedt-Nordenvall, E Gille, J Reizenstein, G Adell, L Farnebo, J Rzepecki, H Haugen, K Söderström, B Zackrisson, S Bergström, B Lödén, L Cederblad, G Laurell, E Smeland, J Folkvard Evensen, J Å Lund, H Tøndel, Å Karlsdottir, J Jóhannsson, J Johansen, C A Kristensen, K Jensen, L J Andersen, P Koivunen, M Korpela, L Voutilainen, T Wigren, H Minn, H Joensuu, J Overgaard, K Saarilahti
No abstract text is available yet for this article.
December 5, 2017: Acta Oncologica
Deirdre Cronin-Fenton, Timothy L Lash, Thomas P Ahern, Per Damkier, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen
BACKGROUND: Myriad reports suggest that frequently used prescription drugs alter the viability of breast cancer cells in pre-clinical studies. Routine use of these drugs, therefore, may impact breast cancer prognosis, and could have important implications for public health. METHODS: The Danish Breast Cancer Group (DBCG) clinical database provides high-quality prospectively collected data on breast cancer diagnosis, treatment, and routine follow-up for breast cancer recurrence...
December 5, 2017: Acta Oncologica
Lena H Rosvig, Sven T Langkjer, Ann Knoop, Anders B Jensen
No abstract text is available yet for this article.
December 5, 2017: Acta Oncologica
Eva Bundesen
No abstract text is available yet for this article.
December 5, 2017: Acta Oncologica
Anne-Vibeke Laenkholm, Dorthe Grabau, Maj-Lis Møller Talman, Eva Balslev, Anne Marie Bak Jylling, Tomasz Piotr Tabor, Morten Johansen, Anja Brügmann, Giedrius Lelkaitis, Tina Di Caterino, Henrik Mygind, Thomas Poulsen, Henrik Mertz, Gorm Søndergaard, Birgitte Bruun Rasmussen
INTRODUCTION: In 2011, the St. Gallen Consensus Conference introduced the use of pathology to define the intrinsic breast cancer subtypes by application of immunohistochemical (IHC) surrogate markers ER, PR, HER2 and Ki67 with a specified Ki67 cutoff (>14%) for luminal B-like definition. Reports concerning impaired reproducibility of Ki67 estimation and threshold inconsistency led to the initiation of this quality assurance study (2013-2015). The aim of the study was to investigate inter-observer variation for Ki67 estimation in malignant breast tumors by two different quantification methods (assessment method and count method) including measure of agreement between methods...
December 5, 2017: Acta Oncologica
Maj-Britt Jensen, Anne-Vibeke Laenkholm, Birgitte V Offersen, Peer Christiansen, Niels Kroman, Henning T Mouridsen, Bent Ejlertsen
BACKGROUND: Since 40 years, Danish Breast Cancer Cooperative Group (DBCG) has provided comprehensive guidelines for diagnosis and treatment of breast cancer. This population-based analysis aimed to describe the plurality of modifications introduced over the past 10 years in the national Danish guidelines for the management of early breast cancer. By use of the clinical DBCG database we analyze the effectiveness of the implementation of guideline revisions in Denmark. METHODS: From the DBCG guidelines we extracted modifications introduced in 2007-2016 and selected examples regarding surgery, radiotherapy (RT) and systemic treatment...
December 5, 2017: Acta Oncologica
Henning Mouridsen, Peer Christiansen, Maj-Britt Jensen, Anne-Vibeke Laenkholm, Henrik Flyger, Birgitte Offersen, Ilse Vejborg, Bent Ejlertsen
No abstract text is available yet for this article.
December 5, 2017: Acta Oncologica
Kristine Hamran, Linnea Langhans, Ilse Vejborg, Tove Filtenborg Tvedskov, Niels Kroman
No abstract text is available yet for this article.
December 5, 2017: Acta Oncologica
Trine Tramm, Marianne Kyndi, Flemming B Sørensen, Jens Overgaard, Jan Alsner
INTRODUCTION: The influence of intra-tumoral heterogeneity on the evaluation of immunohistochemical (IHC) biomarker expression may affect the analytical validity of new biomarkers substantially and hence compromise the clinical utility. The aim of this study was to examine the influence of intra-tumoral heterogeneity as well as inter-observer variability on the evaluation of various IHC markers with potential prognostic impact in breast cancer (BCL2, E-cadherin, EGFR, EMMPRIN and Ki-67)...
December 4, 2017: Acta Oncologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"